

Metformin Adjuncts Studied

BY TIMOTHY F. KIRN
Sacramento Bureau

Sulfonylureas, alpha-glucosidase inhibitors, and possibly glinides have similar efficacy when added on to failing metformin therapy in patients with type 2 diabetes, according to a new meta-analysis.

Thiazolidinediones (TZDs) have less efficacy as an add-on to metformin—that is, less effect in lowering hemoglobin A_{1c}—in the first 6 months, but may become more efficacious over the long term. And insulin as an add-on to failing metformin therapy is not clearly superior to adding on a sulfonylurea, the meta-analysis indicated.

Those results aside, there are few studies on the subject, and the choice of which drug to add for a patient failing metformin

Adjusting for baseline HbA_{1c}, the investigators found that the reduction from adding a sulfonylurea was greater than the reduction from adding a TZD.

cannot clearly be made based on evidence of differences in hypoglycemic efficacy, commented Dr. Matteo Monami and colleagues from the department of critical care medicine and surgery at the University of Florence (Italy).

Differences are not definitively confirmed by the clinical trials, the researchers noted.

The researchers conducted their analysis by searching the U.S. National Library of Medicine's Medline database for randomized clinical trials investigating the efficacy of add-on therapy in patients failing either metformin or another oral antihypoglycemic agent. Limiting their selection to trials that lasted at least 16 weeks, they identified 27 studies that fit their criteria (*Diab. Res. Clin. Pract.* [2007], doi:10.1016/j.diabres.2007.08.024).

In all, 16 of those trials compared an add-on drug with placebo in patients on metformin; 5 of the trials added on a sulfonylurea; 5 trials, an alpha-glucosidase inhibitor; 3 trials, a thiazolidinedione; 2 trials, a glinide; and 1 trial, the glucagon-like peptide 1 agonist exenatide.

Combining data from those trials showed that adding on a sulfonylurea reduced the hemoglobin A_{1c} (HbA_{1c}) level by an average of 0.85%; adding on a thiazolidinedione reduced HbA_{1c} by 0.42%; and adding on an alpha-glucosidase inhibitor reduced HbA_{1c} by 0.61%.

Adjusting for baseline HbA_{1c} level, the investigators found that the reduction from adding a sulfonylurea was greater than the reduction obtained by adding a TZD. But they also found that the difference between a sulfonylurea and an alpha-glucosidase inhibitor was not statistically significant; neither was the difference between an alpha-glucosidase inhibitor and a TZD.

A total of 11 trials were found that compared different agents added on to existing therapy. Combining data from the trials that directly compared a sulfonylurea add-


on with a TZD add-on, the sulfonylurea add-on was found to produce the greater reduction in HbA_{1c}, of 0.17%. In direct comparison of sulfonylurea with insulin, there was no significant difference in the reduction obtained.

Six of the trials were conducted in patients failing metformin therapy. In data from those trials, the sulfonylurea add-on had greater efficacy than the TZD add-on, with a difference in HbA_{1c} of 0.24%.

The data suggesting equivalence between a sulfonylurea and insulin should be viewed with caution, the authors said. The meta-analysis included only two studies addressing that issue; each was only 16 weeks long, they noted. ■



In the mixed dyslipidemic patient **LDL-C may be the first to be addressed, but watch out for other lipid risk factors**



For overall lipid management, address lipid residual risk factors: high TG and low HDL-C¹

Prescribe

TriCor[®] 145 mg
fenofibrate tablets & **48 mg**



References: 1. National Heart, Lung, and Blood Institute. *Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)*. Bethesda, Md: National Institutes of Health; 2002. NIH publication 02-5215. 2. TriCor tablets package insert, Abbott Laboratories.

www.tricortablets.com

Please see adjacent brief summary of Full Prescribing Information

© 2007, Abbott Laboratories Abbott Park, IL 60064 07A-030-S868-1 March 2007 Printed in U.S.A.

DATA WATCH

Adults With the Longest Diabetes Duration Most Likely to Self-Monitor Blood Glucose Daily



Note: Based on 2006 U.S. data.

Source: Centers for Disease Control and Prevention

ELSEVIER GLOBAL MEDICAL NEWS

Indications and Important Safety Information

Type IIa/IIb Indications²: •TriCor is indicated as adjunctive therapy to diet in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson types IIa and IIb) to: increase high-density lipoprotein cholesterol (HDL-C), reduce triglycerides (TG), reduce low-density lipoprotein cholesterol (LDL-C), reduce total cholesterol (Total-C), reduce apolipoprotein B (Apo B). •Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate.

Important Safety Information²: •TriCor is contraindicated in patients with: hypersensitivity to fenofibrate; hepatic or severe renal dysfunction including primary biliary cirrhosis; unexplained persistent liver function abnormality; and preexisting gallbladder disease. •Fenofibrate has been associated with increases in serum transaminases. Regular liver function monitoring should be performed, and therapy discontinued if enzyme levels persist >3 times the normal limit. •Fenofibrate may lead to cholelithiasis. If cholelithiasis is confirmed, TriCor should be discontinued. •TriCor may increase the effects of coumarin-type anticoagulants. Dosage adjustment based on frequent prothrombin time/INR determinations is advisable. •The combined use of TriCor and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk. This combination has been associated with rhabdomyolysis, markedly elevated creatine kinase levels and myoglobinuria, leading to acute renal failure. •TriCor may occasionally be associated with myositis, myopathy, or rhabdomyolysis. Muscle pain, tenderness, or weakness should have prompt medical evaluation. Discontinue TriCor if markedly elevated CPK levels occur or myopathy/myositis is suspected or diagnosed. •The effect of TriCor on coronary heart disease morbidity and mortality and noncardiovascular mortality has not been established. •Other precautions include pancreatitis, hypersensitivity reactions, and hematologic changes. •Adverse events most frequently observed in clinical trials: abnormal liver function tests; respiratory disorder; abdominal pain; back pain; and headache.

Abbott
A Promise for Life